Aastrom Biosciences Inc (ASTM)

3.10
0.01 0.18
NASDAQ : Health Care
Prev Close 3.11
Open 3.10
Day Low/High 3.10 / 3.14
52 Wk Low/High 2.55 / 5.39
Volume 6.30K
Avg Volume 211.70K
Exchange NASDAQ
Shares Outstanding 23.79M
Market Cap 65.77M
EPS -5.18
P/E Ratio N/A
Div & Yield N.A. (N.A)
Biotech Stock Mailbag: Aastrom BioSciences

Biotech Stock Mailbag: Aastrom BioSciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 19, 2010.

Aastrom Presents Positive Second Interim Analysis Of Phase 2b RESTORE-CLI Clinical Trial

Aastrom Presents Positive Second Interim Analysis Of Phase 2b RESTORE-CLI Clinical Trial

Company Continues Its Plans to Rapidly Move Into a Phase 3 Program in 2011

Biotech Sector Weekly Rewind

Biotech Sector Weekly Rewind

Adam Feuerstein's take on the biotech sector's hits and misses during the week ended Nov. 12, 2010.

Aastrom And ATEK Medical Form Strategic Manufacturing And Development Partnership

Aastrom And ATEK Medical Form Strategic Manufacturing And Development Partnership

Collaboration Expected to Generate High-Paying Jobs in Michigan

Aastrom Biosciences Reports Fourth Quarter And Fiscal Year 2010 Operating Results

Company Preparing for Phase 3 Critical Limb Ischemia Clinical Program, Announcement of Final Phase 2 CLI 6-Month Results and Final IMPACT-DCM 6-Month Results

Aastrom Initiates IMPACT-DCM Extension Study For Control Patients

Independent Data Safety Monitoring Board Approves Protocol Amendment for Initiation of Extension Study Involving Control Patients and Encourages Company to Begin Patient Enrollment

Interim Results From Aastrom Critical Limb Ischemia Study Presented Today At Society For Vascular Surgery Annual Meeting

Additional Results Showing Statistically Significant Improvement in Amputation-Free Survival to be Presented by Principal Investigator Richard Powell, M.D.; Webcast and Conference Call Scheduled for 3:30pm EDT

Aastrom Announces Senior Management Appointments

Ronnda L. Bartel, Ph.D., Named Chief Scientific Officer; Sharon Watling, Pharm.D., Appointed Vice President of Clinical and Regulatory Affairs

Interim Results From Aastrom's Vascular Trial To Be Presented At Society For Vascular Surgery Annual Meeting

Principal Investigator Dr. Richard Powell to Present Interim Results From U.S. Phase 2b RESTORE-CLI Trial at the 2010 Vascular Annual Meeting(R) on June 11 in Boston, MA

Aastrom, Broadwind Energy: Late Day Volume Plays

Aastrom, Broadwind Energy: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

Geron, StemCells: Late Day Volume Plays

Geron, StemCells: Late Day Volume Plays

Several stocks trading near $5 were moving on above-average volume during Wednesday's session.

Aastrom Biosciences Receives Delisting Notice

Aastrom Biosciences Receives Delisting Notice

Aastrom Biosciences receives delisting letter from Nasdaq for not remaining in compliance